NCT03333616 2026-01-21Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsDana-Farber Cancer InstitutePhase 2 Active not recruiting100 enrolled
NCT03910660 2025-10-20A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.BioXcel Therapeutics IncPhase 1/2 Completed98 enrolled
NCT04926181 2025-05-15Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate CancerUniversity of California, San FranciscoPhase 2 Terminated2 enrolled 12 charts
NCT05621837 2025-05-02SerpentineFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRecruiting1,000 enrolled